We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Abal Group Plc | LSE:ABAL | London | Ordinary Share | GB00BFMDJC60 | ORD 0.002P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIMTK
RNS Number : 2733Y
Imaginatik PLC
29 February 2012
29 February 2012
Imaginatik plc
("Imaginatik" or the "Company")
Re-engagement with leading US healthcare services provider
Imaginatik plc (AIM: IMTK), a leading provider of enterprise innovation solutions including a range of technology products and consultancy, is pleased to announce the signing of a new annual contract with a leading provider of healthcare services and medical research in the United States, following a competitive tender process.
The contract is comprised of an initial start-up phase worth $120,000 in the current calendar year and is for the provision of Innovation as a Service and innovation consultancy. This is followed by an ongoing annual contract worth $150,000 per year, with Imaginatik supplying its innovation software platform, Innovation Central, to achieve strategic operational objectives.
This is the re-signing of a client which had initially contracted with the Company in 2006, cancelling its contract in March 2010 as a result of budget constraints. This is a strong validation of the increased value attributed to Imaginatik's enhanced full service innovation solutions.
Matt Cooper, Executive Chairman of Imaginatik, commented, "We are delighted that this customer has chosen to re-engage with Imaginatik and we hope to help them build and embed an innovation competence throughout their organisation. This is a strong validation of our unique capability to provide full-service innovation solutions and the value that these services can provide to businesses seeking to be leaders in their industries. Imaginatik continues to take considerable steps forward and we remain confident in the ongoing success of the Company."
For further information please contact:
Imaginatik plc Tel: 020 7917 2975 Matt Cooper, Executive Chairman / Shawn Taylor, CFO Northland Capital Partners Limited Tel: 020 7796 8800 Gavin Burnell / Edward Hutton Newgate Threadneedle Tel: 020 7653 9850 Caroline Evans-Jones / Hilary Millar
About Imaginatik
Imaginatik provides Innovation and Idea management solutions comprised of consultancy, enterprise software and program management to deliver innovation results to companies such as The World Bank, NYSE, The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. This is Imaginatik's area of expertise.
Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Winchester, UK. For more information visit www.imaginatik.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFAPAALAEFF
1 Year Abal Chart |
1 Month Abal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions